Loading
Pamlectabart tismanitin is an experimental antibody-drug conjugate with an amanitin payload from Heidelberg Pharma, in phase 2 trials for relapsed or refractory multiple myeloma.
Pamlectabart tismanitin (HDP-101, BCMA-ATAC) is an antibody-drug conjugate with an amanitin payload (ATAC) from Heidelberg Pharma, with Hangzhou Zhongmei Huadong Pharmaceutical as partner. An antibody-drug conjugate in which a BCMA antibody delivers the toxin amanitin to myeloma cells. Its furthest stage is phase 2, for relapsed or refractory multiple myeloma. ClinicalTrials.gov registers it in 2 studies linked below. Phase I part completed early April 2026; phase IIa dose expansion started (company page). FDA Fast Track Oct 2025, orphan designation March 2024. Whether it works in people has not been established unless a trial below reports it.
An antibody-drug conjugate in which a BCMA antibody delivers the toxin amanitin to myeloma cells. Connects to BCMA.
1.Pamlectabart tismanitin's antibody arm binds BCMA on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Pamlectabart tismanitin" OR ABSTRACT:"Pamlectabart tismanitin" OR TITLE:"HDP-101" OR ABSTRACT:"HDP-101" OR TITLE:"BCMA-ATAC" OR ABSTRACT:"BCMA-ATAC") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Pamlectabart tismanitin, not a curated reading list.
Shares Heidelberg Pharma and the tag pipeline.
Shares BCMA, Relapsed or refractory multiple myeloma and the tag pipeline.
Shares Heidelberg Pharma and the tag pipeline.
Shares BCMA, Relapsed or refractory multiple myeloma and the tag pipeline.
Shares BCMA, Relapsed or refractory multiple myeloma and the tag pipeline.
Shares BCMA, Relapsed or refractory multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/